טוען...
New treatment options for ALK+ advanced non-small-cell lung cancer: critical appraisal of ceritinib
Rearrangements in ALK gene and EML4 gene were first described in 2007. This genomic aberration is found in about 2%–8% of non-small-cell lung cancer (NSCLC) patients. Crizotinib was the first ALK tyrosine kinase inhibitor licensed for the treatment of metastatic ALK-positive NSCLC based on a randomi...
שמור ב:
| הוצא לאור ב: | Ther Clin Risk Manag |
|---|---|
| מחבר ראשי: | |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Dove Medical Press
2016
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4863587/ https://ncbi.nlm.nih.gov/pubmed/27217763 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/TCRM.S87876 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|